Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Eledon Pharmaceuticals is a clinical-stage biotechnology company developing tegoprubart, an anti-CD40L antibody targeting transplant rejection and autoimmune diseases. The company is advancing Phase 2 trials in kidney transplantation and IgA nephropathy, with no commercial revenue and complete dependence on capital markets for funding. Stock performance is driven by clinical trial readouts, regulatory milestones, and financing events.
Eledon operates a binary-outcome clinical development model focused on tegoprubart, targeting the CD40/CD40L pathway to prevent immune rejection. The company burns approximately $20-30M annually on clinical trials and R&D with no revenue generation. Value creation depends entirely on successful Phase 2/3 trial outcomes, FDA approval, and eventual commercialization or acquisition by larger pharmaceutical companies. Current cash runway extends into 2027 based on $135M+ cash position (6.74x current ratio). Pricing power will depend on demonstrating superiority over standard immunosuppression regimens and achieving regulatory approval.
Tegoprubart Phase 2 clinical trial data readouts in kidney transplantation (primary endpoint: acute rejection rates vs. standard of care)
IgA nephropathy trial enrollment milestones and interim safety/efficacy data
FDA regulatory interactions including IND amendments, Fast Track designation decisions, and breakthrough therapy status
Equity financing announcements and dilution events given cash burn rate of $25-30M annually
Partnership or licensing deals with major pharmaceutical companies for commercialization rights
Competitive developments in CD40/CD40L pathway inhibitors or alternative transplant rejection therapies
Binary clinical trial risk: Phase 2/3 failure in kidney transplantation or IgA nephropathy would eliminate primary value drivers and potentially require strategic pivot or wind-down
Regulatory pathway uncertainty for novel immunosuppression mechanisms given FDA's conservative approach to transplant therapies and requirement for long-term safety data
Reimbursement challenges in transplant market where payers scrutinize high-cost biologics versus generic immunosuppressants (tacrolimus, mycophenolate)
Manufacturing scale-up risk for antibody production if trials succeed, requiring CMO partnerships and significant capital investment
Established immunosuppression regimens (calcineurin inhibitors, mTOR inhibitors) have decades of safety data and generic pricing, creating high bar for adoption
Competing CD40/CD40L pathway programs from larger biotechs with superior resources and faster development timelines
Potential for CAR-T or tolerance-inducing therapies to disrupt transplant immunosuppression paradigm entirely
Equity dilution risk: With -$30M annual burn and $100M+ market cap, future financings will significantly dilute existing shareholders
Cash runway pressure if trials extend beyond 2027 timeline or require additional studies for regulatory approval
Minimal debt provides limited financial flexibility but also means no covenant protection; equity is only funding source
low - Clinical trial timelines and regulatory processes are largely insulated from GDP fluctuations. However, severe recessions can impact venture capital availability and biotech IPO/financing markets, affecting ability to raise capital. Patient enrollment may slow marginally during economic stress but transplant procedures remain medically necessary.
Rising interest rates negatively impact valuation multiples for pre-revenue biotechs as discount rates increase on future cash flows (5-10 years out). Higher rates also reduce risk appetite for speculative growth stocks, compressing biotech sector multiples. Financing costs increase for any debt facilities, though Eledon maintains minimal debt (0.02 D/E ratio). Cash holdings benefit from higher yields on treasury investments.
Minimal direct credit exposure. Company depends on equity capital markets rather than debt financing given negative cash flows. Tightening credit conditions indirectly impact biotech sector sentiment and institutional investor risk appetite, making equity raises more dilutive or difficult to execute.
growth - Attracts speculative biotech investors focused on binary clinical catalysts and potential 5-10x returns on FDA approval. High-risk, high-reward profile appeals to venture capital, biotech-focused hedge funds, and retail momentum traders. Not suitable for value or income investors given negative earnings and no dividend. Recent 37% 3-month rally suggests momentum following positive clinical updates or sector rotation.
high - Clinical-stage biotechs exhibit extreme volatility around data readouts (±30-50% single-day moves). $100M market cap and low float amplify price swings. 54% one-year decline reflects sector-wide biotech correction and likely financing overhang. Beta likely exceeds 2.0x relative to broader market.
